Omeros stock
OMERNASDAQOmeros Corporation, HealthcareISIN US6821431029
52Score 52 out of 100, Neutral
Price and trend
77 / 100
Price history
+163% in one yearThe chart shows daily closes over 17 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 32% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 58).
The price is 14% below its 52-week high. Largest decline in 17 years: 96% (September 2018 to October 2023).
Chart figures for advanced users
- SMA 50$18.32
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$13.71
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)58
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.28
- The lowest closing price of the last twelve months.
- Resistance$21.05
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Omeros Corporation belongs to the Biotechnology industry (United States) and, with a market value of $1.31B, is number 171 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 52 out of 100 (Neutral): rank 370 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 100% over the last 12 months, Biotechnology median −93.3%.Profitability 67
Weaknesses
- Volatile share priceVolatility 111% a year over the last 12 months.Stability 44
- Negative free cash flowFree cash flow −$68.73M over the last 12 months.Fundamentals 18
- DilutionShare count up 11% since 2020.Capital allocation 18
Its standout strengths are momentum and technical analysis, while fundamentals and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 50 to 52.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
- price up very strongly over the past year
Valuation
Valuation signal
Possible value trapNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Possible value trap: looks cheap, but weak balance sheet.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net not measured.
Debt & balance sheet
Fiscal 2025Debt is elevated; no interest coverage is reported.
Earnings
- Next earnings
- 16 Nov 2026in 4 days
- Last reported
- 13 Aug 2026EPS reported $0.15 (expected −$0.27)above expectations
Analyst estimates
- Earnings per share
- $0.83−9.0%
- Revenue
- $127.51M0.0%
- Earnings per share
- $1.06+0.1%
- Revenue
- $221.32M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +27.6%No revenue guidance; higher research and sales and marketing expenses and interest expense of about $6.5 million are expected for the third quarter.
“We remain focused on expanding physician awareness and disease education and ensuring continued timely reimbursement Interest and other income are expected to be lower in the third quarter primarily because the Novo Nordisk inventory reimbursement recognized in the second quarter will not recur Interest expense is …”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 12 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $2.08M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Borges David J.Sale
23 Sept 2026, VP, Finance & CAO
- Shares
- 10,000
- Price
- $20.95
- Value
- $209,500
- Cancelmo Peter BSale
31 Aug 2026, VP, General Counsel
- Shares
- 25,000
- Price
- $18.54
- Value
- $463,540
- Cancelmo Peter BSale
28 Aug 2026, VP, General Counsel
- Shares
- 25,000
- Price
- $18.65
- Value
- $466,128
Show 7 more
- Hanish Arnold CSale
27 Aug 2026, Board
- Shares
- 10,000
- Price
- $18.95
- Value
- $189,462
- Hanish Arnold CSale
26 Aug 2026, Board
- Shares
- 5,000
- Price
- $18.53
- Value
- $92,633
- Borges David J.Sale
24 Aug 2026, VP, Finance & CAO
- Shares
- 906
- Price
- $19.10
- Value
- $17,305
- Borges David J.Sale
21 Aug 2026, VP, Finance & CAO
- Shares
- 10,000
- Price
- $18.95
- Value
- $189,500
- Cable Thomas J.Sale
20 Aug 2026, Board
- Shares
- 15,000
- Price
- $18.45
- Value
- $276,773
- Borges David J.Sale
13 Aug 2026, VP, Finance & CAO
- Shares
- 5,000
- Price
- $16.95
- Value
- $84,750
- Cable Thomas J.Sale
22 May 2026, Board
- Shares
- 7,500
- Price
- $11.61
- Value
- $87,039
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Omeros
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 52
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Pharma MarPHM.MC $1.34B59
- Inhibrx BiosciencesINBX $1.33B34
- GH ResearchGHRS $1.32B37
- COMPASS PathwaysCMPS $1.32B35
- IdorsiaIDIA.SW $1.3B36
- Alpha Tau MedicalDRTS $1.3B43
- Rapport TherapeuticsRAPP $1.3B33
- UroGen PharmaURGN $1.28B36
ETFs that hold Omeros
Held by 9 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.08% | 0.35% | €1.21B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.04% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.04% | 0.30% | €2.17B |
Show 5 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €944.34M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.6B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.